|Videos|November 17, 2022
Patient Profiles: Transplant-Ineligible Newly-Diagnosed Multiple Myeloma
Drs Tuchman and Gasparetto present two profiles of patients with transplant-ineligible NDMM.
Advertisement
Episodes in this series
Advertisement
Related to this article
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Advertisement
Advertisement
Trending on CancerNetwork
1
Building Systems to Catch Liver and Other Cancers in Patients With MASLD
2
Closing the HCC Surveillance Gap in MASLD Without Cirrhosis
3
Rethinking Surveillance and Multidisciplinary Care in MASLD-Related HCC
4
Weighing HCC Surveillance for Patients With MASLD and F3 Fibrosis
5